The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives

Journal of Clinical Hypertension

Volumn 12, Issue 3, 2010, Pages 153-159

  Germino, F Wilford ^a   Neutel, Joel ^b   Nonaka, Mako ^c   Hendler, Sheldon S ^d  

^a From the Department of Internal Medicine   (United States)

^b Orange County Research Center   (United States)

^c The Foundation for International Scientific Advancement   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMEALPEPTIDE; ANTIHYPERTENSIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSPECTIVE STUDIES;

EID: 77950123764     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00250.x     Document Type: Article

References (16)

1. Heart Disease and Stroke Statistics 2008, American Heart Association, Update
2. Vasan RS, Larson MG, Leip EP. Assessment of the frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study. Lancet 2001, 358:1682-1686.
3. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993, 153:598-615.
4. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
5. Neter JE, Stam BE, Kok FJ. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
6. MacGregor GA, Markandu ND, Sagnella GA. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989, 2:1244-1247.
7. Xin X, He J, Frontini MG. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001, 38:1112-1117.
8. Appel LJ, Moore TJ, Obarzanek E. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 1997, 336:117-1124.
9. Nakamura Y. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin1-converting enzyme. J Dairy Sci 1995, 78:1253-1257.
10. Jauhiainen T. Milk peptides and blood pressure. J Nutr 2007, 137:825S-9.
11. Engberink MF, Schouten EG, Krok FJ. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension 2008, 51:399-405.
12. Van der Zander K, Bots ML, Bak AAA. Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. Am J Clin Nutr 2008, 88:1697-1702.
13. Van Mierlo LJL, Koning MMG, van derZander K. Lactotripeptides do not lower amnulatory blood pressure in untreated white:results of 2 controlled mulitcenter crossover studies. Am J Clin Nutr 2009, 89:617-623.
14. Xu JY, Qin LQ, Wang PY. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition 2008, 24:933-940.
15. Vasan RS, Larson MG, Leip EP. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
16. Stamler R. Implications of the INTERSALT Study. Hypertension 1991, 17:116-120.